Molecular Mechanisms of HPV-Driven Cervical Carcinogenesis: From Viral Persistence to Malignant Transformation

The management of human papillomavirus (HPV)-driven cervical carcinoma (CC) necessitates a comprehensive understanding of the interplay between viral oncogenesis and host cellular dysregulation. Future clinical strategies are increasingly focused on biomarker-guided interventions that target the specific pathways hijacked by the virus to sustain its life cycle and drive oncogenic transformation.

HPV, a small, double-stranded DNA virus, specifically targets the stratified squamous epithelium. Infection is initiated when micro-abrasions expose the basal layer of the cervical epithelium, allowing viral access to basal keratinocytes via heparan sulfate proteoglycans (HSPGs) and the α6/β4 integrin complex. Once internalized, the viral genome is transported to the nucleus, where it persists as an episome. The intricate regulation of the HPV life cycle is categorized in the table below:

While most infections are transient, persistent high-risk HPV (HR-HPV) infection is the primary determinant of cervical carcinogenesis. Current research, utilizing resources such as the Gene Ontology database to analyze functional genomic shifts, highlights how persistent expression of E6 and E7 oncoproteins overrides host cell cycle checkpoints. E6 targets the tumor suppressor p53 for proteasomal degradation, while E7 inactivates the retinoblastoma protein (pRb), releasing E2F transcription factors to force S-phase entry. These molecular events mirror the complex biological processes managed at leading research institutions like the RIKEN Center for Biosystems Dynamics Research , where the integration of cell signaling and tissue architecture is a primary focus.

Emerging research has expanded the understanding of HPV-associated tumor biology beyond simple cell cycle disruption to include the modulation of programmed cell death pathways. Emerging evidence suggests that the evasion of pyroptosis, necroptosis, and the integrated PANoptosis pathway significantly influences the immune microenvironment and therapeutic sensitivity in CC. Furthermore, the disruption of cell polarity through the E6-mediated degradation of PDZ-domain proteins (such as DLG1 and SCRIB) dismantles epithelial junctional integrity. This loss of structural control contributes to the accumulation of centrosomal duplication errors and chromosomal instability, ultimately facilitating the progression from high-grade cervical intraepithelial neoplasia (CIN) to invasive carcinoma.

By effectively manipulating host machinery, HPV not only secures its own replication but also establishes a landscape of genomic and epigenetic instability. Future therapeutic efforts must therefore address these coordinated disruptions—spanning cell death evasion, loss of contact inhibition, and mitotic dysregulation—to effectively transform the clinical management of HPV-driven malignancies.